In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, which would save the company $1 billion over the next two years Global drugmaker Novartis will lay off 427 employees in ...

TOKYO, March 17 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early ...

Novartis is just months away from filing for ... and multiple sclerosis (MS), and in phase 2 for hidradenitis suppurativa (HS) and food allergy. Analysts have suggested that approval in CSU ...

When Vas Narasimhan started as the new CEO of the Swiss drug giant Novartis, he began refocusing the company on a key business area: prescription medicines. Until recently, alongside top-selling ...

CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024 ... driven by new launches in HS and IV formulations. The brand remains a leader in the IL-17 category across key markets.

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero Prostate Cancer’s Blitz the Barriers, a project designed to address ...

Novartis AG NVS, a Swiss pharma giant ... including the hidradenitis suppurativa indication (HS) and the intravenous formulation (IV) in the United States, and volume growth in core indications.

ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...

This article was coproduced with Kody Kester. Since last October, Novartis' shares have lagged the S&P 500 index. The pharmaceutical company's pipeline remains robust, which could translate into ...

Novartis has a 12 month low of $92.35 and a 12 month high of $120.92. Get Novartis alerts: Novartis (NYSE:NVS – Get Free Report) last announced its quarterly earnings results on Friday ...